Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Liu, Yongsheng; Xu, Tianqi; Vorobyeva, Anzhelika; Loftenius, Annika; Bodenko, Vitalina; Orlova, Anna; Frejd, Fredrik Y.; Tolmachev, Vladimir

doi:10.3390/cancers15092409

Cited by 9 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same antitumor effect was also observed when 131 I-NM-02, another nanobody, was used in HER2positive xenografts [151]. 177 Lu-ABY-027 affibody was also evaluated for its ability to treat HER2-positive tumors and showed higher efficacy when combined with trastuzumab in comparison to monotherapies [152].…”

Section: Human Epidermal Growth Factor Receptor 2 (Her2) Targetingmentioning

confidence: 62%

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Echavidre,

Fagret,

Faraggi

et al. 2023

Cancers

View full text Add to dashboard Cite

The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.

show abstract

Section: Human Epidermal Growth Factor Receptor 2 (Her2) Targetingmentioning

confidence: 62%

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Echavidre,

Fagret,

Faraggi

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Affibody imaging tracers may therefore find application in theranostic pairs consisting of an Affibody-imaging agent followed by targeted molecular radiotherapy. The concept of such an Affibody-based radiotherapy has previously been explored preclinically with promising results [76]. Translation of this approach into clinical development of an HER2-targeted radioligand would highly benefit from the HER2-Affibody imaging technology.…”

Section: Future Directionsmentioning

confidence: 99%

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy

Eissler,

Altena,

Alhuseinalkhudhur

et al. 2024

Preprint

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) is a major prognostic and predictive marker overexpressed in 15- 20 % of breast cancers. The diagnostic reference standard for selecting patients for HER2-targeted therapy is by analysis of tumor biopsies for HER2 expression and amplification. Previously patients were either defined as HER2-positive or negative, however, with approval of novel treatment options, specifically the antibody-drug conjugate trastuzumab deruxtecan, many breast cancer patients with tumors expressing low levels of HER2 and lacking HER2 amplification have become eligible for HER2-targeted therapy. Such patients will need to be reliably identified by suitable diagnostic methods. Biopsy-based diagnostics are invasive, and repeat biopsies are not always feasible. They cannot visualize heterogeneity of HER2 expression, leading to a substantial number of misdiagnosed patients. An alternative and highly accurate diagnostic method is mo-lecular imaging with radiotracers. In case of HER2, various studies demonstrate the clinical utility and feasibility of such approaches. Affibody-based radiotracers are clinically validated molecules with favorable characteristics for imaging. In this article we summarize the HER2-targeted therapeutic landscape, describe the experience with imaging diagnostics for HER2, and review the currently available clinical data on HER2-Affibody-based molecular imaging as novel diagnostic tool in breast cancer and beyond.

show abstract

“…Affibody imaging tracers may therefore find application in theranostic pairs consisting of an Affibody-imaging agent followed by targeted molecular radiotherapy. The concept of such an Affibody-based radiotherapy has been explored preclinically with promising results [78]. The translation of this approach into the clinical development of an HER2-targeted radioligand would highly benefit from the HER2-Affibody imaging technology.…”

Section: Future Directionsmentioning

confidence: 99%

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy

Eissler,

Altena,

Alhuseinalkhudhur

et al. 2024

Biomedicines

Self Cite

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) is a major prognostic and predictive marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for selecting patients for HER2-targeted therapy is based on the analysis of tumor biopsies. Previously patients were defined as HER2-positive or -negative; however, with the approval of novel treatment options, specifically the antibody–drug conjugate trastuzumab deruxtecan, many breast cancer patients with tumors expressing low levels of HER2 have become eligible for HER2-targeted therapy. Such patients will need to be reliably identified by suitable diagnostic methods. Biopsy-based diagnostics are invasive, and repeat biopsies are not always feasible. They cannot visualize the heterogeneity of HER2 expression, leading to a substantial number of misdiagnosed patients. An alternative and highly accurate diagnostic method is molecular imaging with radiotracers. In the case of HER2, various studies demonstrate the clinical utility and feasibility of such approaches. Radiotracers based on Affibody® molecules, small, engineered affinity proteins with a size of ~6.5 kDa, are clinically validated molecules with favorable characteristics for imaging. In this article, we summarize the HER2-targeted therapeutic landscape, describe our experience with imaging diagnostics for HER2, and review the currently available clinical data on HER2-Affibody-based molecular imaging as a novel diagnostic tool in breast cancer and beyond.

show abstract

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Cited by 9 publications

References 43 publications

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy

Contact Info

Product

Resources

About